Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 8/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199638 | 1.00 | MCHR1 (0.59) | MCHR1TP53MAPTSMN1; SMN2ACHE | |
| SCHEMBL6198941 | 0.89 | MCHR1 (0.65) | MCHR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL6198936 | 0.89 | MCHR1 (0.65) | MCHR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL6203830 | 0.87 | MCHR1 (0.55) | MCHR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL6203837 | 0.87 | MCHR1 (0.55) | MCHR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL6203005 | 0.86 | MCHR1 (0.55) | MCHR1ACHE | |
| SCHEMBL6203011 | 0.86 | MCHR1 (0.55) | MCHR1ACHE | |
| SCHEMBL23758881 | 0.78 | MCHR1 (0.76) | MCHR1MAPTBLM | |
| SCHEMBL6203293 | 0.77 | MCHR1 (0.78) | MCHR1 | |
| SCHEMBL6204610 | 0.77 | MCHR1 (0.78) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050009815-A1 | 4-Aminoquinoline compounds | DEVITA ROBERT J (US) | 2005-01-13 | — | — | US | claimed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009815-A1 | 4-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885TP53 3217/4885MAPT 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.